Results 61 to 70 of about 333,288 (246)

Effect of the TAAR1 Partial Agonist Ralmitaront on Presynaptic Dopamine Synthesis Capacity Measured Using [F]DOPA PET in Naïve and Cocaine-Treated Mice

Molecular Imaging
Purpose Elevated dopamine synthesis capacity is part of the pathophysiology of schizophrenia thought to underlie psychosis. Drugs that reduce this phenomenon could thus be potential treatments for these disorders.
David R. Bonsall PhD, Michelle Kokkinou PhD, Els F. Halff PhD, Grazia Rutigliano PhD, Sac-Pham Tang MSc, Mattia Veronese PhD, Elaine E. Irvine PhD, Dominic J. Withers FRCP, PhD, Lisa A. Wells PhD, Sridhar Natesan PhD, Irene Gerlach PhD, Štefan Holiga PhD, Marius C. Hoener PhD, Oliver D. Howes MRCpsych, PhD   +13 more
doaj   +1 more source

Propofol Modulates Fear Memory Reconsolidation by Inhibiting D2 Receptor‐Expressing Neurons in the Medial Prefrontal Cortex

Advanced Science, EarlyView.
This study shows that propofol modulates fear‐memory reconsolidation in mice. It works by suppressing D2 receptor‐expressing neurons within the medial prefrontal cortex and their connections to the basolateral amygdala. D2‐receptor agonists reproduce this fear‐reducing effect, offering potential non‐anesthetic therapeutic strategies for trauma‐related ...
Jie Li, Yi‐Ge Guo, Xing Xu, Gui‐Lin Meng, Han Li, Liu‐Wei Chu, Xin‐Yuan Chen, Xiao‐Yun Guo, Tao Xu, Ti‐Fei Yuan, Ji Hu, Xiao‐Na Zhu   +11 more
wiley   +1 more source

Cabergoline-induced mania in a patient of pituitary microadenoma

Indian Journal of Psychological Medicine, 2017
Cabergoline, a dopamine agonist agent, is commonly used in the treatment of hyperprolactinemia, Parkinson's disease, restless leg syndrome, and antipsychotic-induced prolactin elevation.
Satyakam Mohapatra, Mihir Ranjan Nayak
doaj   +1 more source

Dopamine induces optical changes in the cichlid fish lens. [PDF]

PLoS ONE, 2010
The crystalline lens in the cichlid fish Aequidens pulcher undergoes a transformation of its optical properties every dawn and dusk as the eye adapts to changes in light conditions.
J Marcus Schartau, Ronald H H Kröger, Bodil Sjögreen   +2 more
doaj   +1 more source

Dopamine agonist switching in Parkinson's disease

, 2004
There are a number of situations for patients with Parkinson's disease in which a safe and efficacious switch from treatment with one dopamine agonist to another may be required.
Macphee, Graeme, MacMahon, Douglas, Heywood, Peter, Grosset, Donald, Stewart, David, Morgan, Elizabeth, Burn, David, Needleman, Fiona, Chaudhuri, K Ray, Grosset, D., Needleman, F., MacPhee, G., Morgan, B., Heywood, P., Stewart, D., MacMahon, D., Burn, D., Chaudhuri, K.R.   +17 more
core   +1 more source

Severe Headbanging Responsive to Levodopa in a Child With FOXP1 Syndrome

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT We report a 9‐year‐old female with FOXP1 syndrome due to a de novo in‐frame deletion in the FOXP1 gene. The child has a severe neurodevelopmental disorder including global developmental delay and autism spectrum disorder. At age 2, she developed severe headbanging, which was progressive and did not respond to multidisciplinary, behavioral ...
Pamela Veale, Christopher Tiessen, Vithya Gnanakumar   +2 more
wiley   +1 more source

DOPAMINE AGONIST SUPPRESSION OF RAPID-EYE-MOVEMENT SLEEP IS SECONDARY TO SLEEP SUPPRESSION MEDIATED VIA LIMBIC STRUCTURES (CIRCADIAN, DEPRIVATION).

, 1985
DOPAMINE AGONIST SUPPRESSION OF RAPID-EYE-MOVEMENT SLEEP IS SECONDARY TO SLEEP SUPPRESSION MEDIATED VIA LIMBIC STRUCTURES (CIRCADIAN, DEPRIVATION)
ROBERT STEVEN. MILETICH (7981628)
core   +4 more sources

Enhancing Meat Quality Through Dietary Fiber: Insights Into the Gut Microbiota‐Derived Short‐Chain Fatty Acids‐Muscle Axis

Animal Research and One Health, EarlyView.
Dietary fiber (DF) modulates meat quality through the gut‐muscle axis by reshaping gut microbiota, improving intestinal integrity, reducing inflammation, and regulating muscle metabolism. These mechanisms influence muscle fiber characteristics and post‐mortem biochemistry, thereby enhancing tenderness, juiciness, color, flavor, and nutritional value of
Zeshan Zulfiqar, Muhammad Arslan Asif, Layla Al‐Mitib, Nabeela Ashiq, Haojie Wang, Yalei Cui, Boshuai Liu, Shucheng Huang, Yinghua Shi   +8 more
wiley   +1 more source

Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study

, 2019
Context: Dopamine agonist (DA)-induced impulse control disorder (ICD) in patients with prolactinomas is not sufficiently ...
Oruk, Gonca, Cikrikcili, Ugur, Tanrikulu, Seher, Dogansen, Sema Ciftci, Gorar, Suheyla, Mert, Meral, Yarman, Sema, Omma, Tulay, Yalin, Gulsah Yenidunya, Kutbay, Nilufer Ozdemir, Ozkan, Mine, Akbaba, Gulhan, BAYRAM, FAHRİ, Ozkan M., HEKİMSOY, ZELİHA, Tanrikulu S., Hekimsoy Z., Omma T., Hadzalic A., Oruk G., Kutbay, NİLÜFER, Cikrikcili U., Akbaba G., Yarman S., Kutbay N.O., Yalin G.Y., Mert M., Hadzalic, Aysa, Gorar S., Dogansen S.C., Bayram F.   +30 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source